These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27690339)

  • 1. Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients.
    Simioniuc A; Carluccio E; Ghio S; Rossi A; Biagioli P; Reboldi G; Galeotti GG; Lu F; Zara C; Whalley G; Temporelli PL; Dini FL;
    Int J Cardiol; 2016 Dec; 224():416-423. PubMed ID: 27690339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echo and BNP serial assessment in ambulatory heart failure care: Data on loop diuretic use and renal function.
    Dini FL; Simioniuc A; Carluccio E; Ghio S; Rossi A; Biagioli P; Reboldi G; Galeotti GG; Lu F; Zara C; Whalley G; Temporelli PL
    Data Brief; 2016 Dec; 9():1074-1076. PubMed ID: 27921080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure.
    Feola M; Aspromonte N; Canali C; Ceci V; Giovinazzo P; Milani L; Quarta G; Ricci R; Scardovi AB; Uslenghi E; Valle R
    Am J Cardiol; 2005 Sep; 96(5):705-9. PubMed ID: 16125500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
    Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
    Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic stratification of patients with chronic systolic heart failure using biomarkers and Doppler echocardiography.
    Ghio S; Alessandrino G; Albertini R; Klersy C; Girardi B; Maggi G; Pazzano AS; Raineri C; Scelsi L; Visconti LO
    J Cardiovasc Med (Hagerstown); 2014 Jun; 15(6):470-5. PubMed ID: 24983266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
    Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
    Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure.
    Pfister R; Müller-Ehmsen J; Hagemeister J; Hellmich M; Erdmann E; Schneider CA
    Intern Med J; 2011 Jun; 41(6):467-72. PubMed ID: 20214692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echo- and B-Type Natriuretic Peptide-Guided Follow-Up versus Symptom-Guided Follow-Up: Comparison of the Outcome in Ambulatory Heart Failure Patients.
    Bajraktari G; Pugliese NR; D'Agostino A; Rosa GM; Ibrahimi P; Perçuku L; Miccoli M; Galeotti GG; Fabiani I; Pedrinelli R; Henein M; Dini FL
    Cardiol Res Pract; 2018; 2018():3139861. PubMed ID: 30363950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BNP-guided therapy optimizes the timing of discharge and the medium term risk stratification in patients admitted for congestive heart failure].
    Valle R; Aspromonte N; Carbonieri E; De Michele G; Di Tano G; Giovinazzo P; Cioè R; Di Giacomo T; Milani L; Noventa F; Chiatto M
    Monaldi Arch Chest Dis; 2007 Sep; 68(3):154-64. PubMed ID: 18361212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
    Pfisterer M; Buser P; Rickli H; Gutmann M; Erne P; Rickenbacher P; Vuillomenet A; Jeker U; Dubach P; Beer H; Yoon SI; Suter T; Osterhues HH; Schieber MM; Hilti P; Schindler R; Brunner-La Rocca HP;
    JAMA; 2009 Jan; 301(4):383-92. PubMed ID: 19176440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.
    Chen HH; Glockner JF; Schirger JA; Cataliotti A; Redfield MM; Burnett JC
    J Am Coll Cardiol; 2012 Dec; 60(22):2305-12. PubMed ID: 23122795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome.
    Karlström P; Alehagen U; Boman K; Dahlström U;
    Eur J Heart Fail; 2011 Oct; 13(10):1096-103. PubMed ID: 21715446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transthoracic bioimpedance and brain natriuretic peptide assessment for prognostic stratification of outpatients with chronic systolic heart failure.
    Malfatto G; Corticelli A; Villani A; Giglio A; Della Rosa F; Branzi G; Facchini M; Parati G
    Clin Cardiol; 2013 Feb; 36(2):103-9. PubMed ID: 23377871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
    Abulhul E; McDonald K; Martos R; Phelan D; Spiers JP; Hennessy M; Baugh J; Watson C; O'Loughlin C; Ledwidge M
    Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric risk stratification in patients with mild to moderate chronic heart failure.
    Scardovi AB; De Maria R; Coletta C; Aspromonte N; Perna S; Cacciatore G; Parolini M; Ricci R; Ceci V
    J Card Fail; 2007 Aug; 13(6):445-51. PubMed ID: 17675058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-type natriuretic peptide. Guided vs. conventional care in outpatients with chronic heart failure: a retrospective study.
    De Vecchis R; Esposito C; Di Biase G; Ariano C
    Minerva Cardioangiol; 2013 Aug; 61(4):437-49. PubMed ID: 23846010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining blood flow and tissue Doppler imaging with N-terminal pro-type B natriuretic peptide for risk stratification of clinically stable patients with systolic heart failure.
    Dini FL; Rosa GM; Fontanive P; Santonato V; Napoli AM; Ciuti M; Di Bello V
    Eur J Echocardiogr; 2010 May; 11(4):333-40. PubMed ID: 20051423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.